Basilea Pharmaceutica Aktie

57,30 EUR -0,80 EUR -1,38 %

16:17:41

STU

52,48 CHF -1,08 CHF -2,01 %

16:21:20

BRX

Basilea Pharmaceutica jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.746,95 Mio. EUR

KGV16,64Div. Rendite0,00%

WKNA0B9GA

ISINCH0011432447

SymbolBPMUF

Basilea Pharmaceutica Aktien News

Sortieren:Datum Meistgelesen

13.11.23GlobeNewswireBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

13.11.23Dow JonesPress Release: Basilea announces acquisition of -2-

31.10.23GlobeNewswireBasilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

31.10.23Dow JonesPress Release: Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

19.10.23GlobeNewswireBasilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

19.10.23Dow JonesPress Release: Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections

17.10.23GlobeNewswireBasilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023

17.10.23Dow JonesPress Release: Basilea reports new data for -2-

02.10.23GlobeNewswireBasilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

02.10.23Dow JonesPress Release: Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

28.09.23GlobeNewswireBasilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

28.09.23Dow JonesPress Release: Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacte...

15.08.23Dow JonesPress Release: Basilea reports strong revenue and profit growth in first half-year 2023

15.08.23GlobeNewswireBasilea reports strong revenue and profit growth in first half-year 2023

04.08.23GlobeNewswireBasilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

04.08.23Dow JonesPress Release: Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

08.06.23GlobeNewswireContinued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

08.06.23Dow JonesPress Release: Continued strong Cresemba(R) (isavuconazole) sales by Pfizer trigger USD26million sales milestone payments to Basilea

18.04.23Dow JonesPress Release: Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole

23.03.23Dow JonesPress Release: Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba(R) (isavuconazole) in Japan

14.02.23Dow JonesPress Release: Basilea reports strong financial -2-

14.02.23Dow JonesPress Release: Basilea reports strong financial results 2022 based on successful implementation of new strategy

07.02.23Dow JonesPress Release: Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea fr...

24.01.23Dow JonesPress Release: Basilea reports preliminary operating profit for 2022, significantly above guidance

11.01.23Dow JonesPress Release: Basilea reports preliminary 2022 -2-

11.01.23Dow JonesPress Release: Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

09.01.23Dow JonesPress Release: Continued strong Cresemba(R) (isavuconazole) sales by Astellas in the U.S. trigger CHF20million sales milestone payment to Basilea

28.12.22Dow JonesPress Release: Basilea announces repayment of 2022 convertible bonds

23.12.22Dow JonesPress Release: Basilea announces regulatory approval of antifungal Cresemba(R) (isavuconazole) in Japan

19.12.22Dow JonesPress Release: Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD4million by SillaJen

02.11.22Dow JonesPress Release: Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

24.10.22Dow JonesPress Release: Basilea: ERADICATE phase 3 study -2-

24.10.22Dow JonesPress Release: Basilea: ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)

21.09.22Dow JonesPress Release: Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

20.09.22Dow JonesPress Release: Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

08.09.22Dow JonesPress Release: Basilea announces sale of preclinical oncology program to Nodus Oncology

07.09.22Dow JonesPress Release: Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December...

16.08.22Dow JonesPress Release: Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy

12.07.22Dow JonesPress Release: Basilea announces Zevtera(R) (ceftobiprole) marketing authorization in Brazil

28.06.22Dow JonesPress Release: Basilea announces positive results -2-

Basilea Pharmaceutica News

Basilea Pharmaceutica News: auf dieser Seite finden Sie alle Basilea Pharmaceutica News und Nachrichten zur Basilea Pharmaceutica Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Basilea Pharmaceutica News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Basilea Pharmaceutica News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.